Ying Huang resigns and Carvykti president Alan Bash is named interim CEO after Legend slides about 33%+ since June's $226 million raise.
Legend Biotech, the developer of the blockbuster cancer therapy Carvykti, is in the market for a new CEO.
Ying Huang stepped down Friday after serving …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
On paper, it was another strong quarter for Carvykti. Johnson & Johnson reported record sales for the CAR-T therapy, signaling…
Capricor shares lost much of their value ahead of a high-stakes advisory committee meeting. Elsewhere, Ying Huang’s resignation…
Legend Biotech’s long-awaited first showing of in vivo CAR-T data is here, fueling momentum in the growing field.
Pfizer CFO exits; GSK wins FDA nod for oral UTI drug; Apellis trial paused; plus Mersana ADC dropped, TORL ADC data, Corcept…
As the chair of Japan’s second-biggest business lobby, Takeshi Niinami has been an outspoken and influential voice in business…
Longtime Allogene CEO David Chang will be stepping down at the end of June. Chang has served as the company’s CEO for the past…
